H. Lundbeck A/S - Product Pipeline Review - 2016

Date: March 22, 2016
Pages: 59
Price:
US$ 1,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H8C1B9C128CEN
Leaflet:

Download PDF Leaflet

H. Lundbeck A/S - Product Pipeline Review - 2016
H. Lundbeck A/S - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘H. Lundbeck A/S - Product Pipeline Review - 2016’, provides an overview of the H. Lundbeck A/S’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by H. Lundbeck A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the pipeline therapeutic landscape of H. Lundbeck A/S
  • The report provides overview of H. Lundbeck A/S including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses H. Lundbeck A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features H. Lundbeck A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate H. Lundbeck A/S’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for H. Lundbeck A/S
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding H. Lundbeck A/S’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
H. Lundbeck A/S Snapshot
H. Lundbeck A/S Overview
Key Information
Key Facts
H. Lundbeck A/S - Research and Development Overview
Key Therapeutic Areas
H. Lundbeck A/S - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
H. Lundbeck A/S - Pipeline Products Glance
H. Lundbeck A/S - Late Stage Pipeline Products
Filing rejected/Withdrawn Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
H. Lundbeck A/S - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
H. Lundbeck A/S - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
H. Lundbeck A/S - Drug Profiles
carbamazepine
Product Description
Mechanism of Action
R&D Progress
idalopirdine
Product Description
Mechanism of Action
R&D Progress
LuAF-35700
Product Description
Mechanism of Action
R&D Progress
nalmefene
Product Description
Mechanism of Action
R&D Progress
vortioxetine hydrobromide
Product Description
Mechanism of Action
R&D Progress
LuAF-11167
Product Description
Mechanism of Action
R&D Progress
LUAF-20513
Product Description
Mechanism of Action
R&D Progress
LUAF-64280
Product Description
Mechanism of Action
R&D Progress
AF-40431
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize nAChR Alpha-4 Beta-2 for Brain Diseases
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit LRRK-2 for Parkinson's Disease
Product Description
Mechanism of Action
R&D Progress
H. Lundbeck A/S - Pipeline Analysis
H. Lundbeck A/S - Pipeline Products by Target
H. Lundbeck A/S - Pipeline Products by Route of Administration
H. Lundbeck A/S - Pipeline Products by Molecule Type
H. Lundbeck A/S - Pipeline Products by Mechanism of Action
H. Lundbeck A/S - Recent Pipeline Updates
H. Lundbeck A/S - Dormant Projects
H. Lundbeck A/S - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
gaboxadol
LuAA-47070
idalopirdine
Lu-02750
Lu-35138
Lu-AA24493
LuAA-37096
LuAA-38466
LuAA-39959
LuAA-44608
LuAE-04621
ORE-10002
siramesine
tedatioxetine hydrobromide
vortioxetine hydrobromide
zicronapine
H. Lundbeck A/S - Company Statement
H. Lundbeck A/S - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

H. Lundbeck A/S, Key Information
H. Lundbeck A/S, Key Facts
H. Lundbeck A/S - Pipeline by Indication, 2016
H. Lundbeck A/S - Pipeline by Stage of Development, 2016
H. Lundbeck A/S - Monotherapy Products in Pipeline, 2016
H. Lundbeck A/S - Partnered Products in Pipeline, 2016
H. Lundbeck A/S - Partnered Products/ Combination Treatment Modalities, 2016
H. Lundbeck A/S - Out-Licensed Products in Pipeline, 2016
H. Lundbeck A/S - Out-Licensed Products/ Combination Treatment Modalities, 2016
H. Lundbeck A/S - Filing rejected/Withdrawn, 2016
H. Lundbeck A/S - Phase III, 2016
H. Lundbeck A/S - Phase II, 2016
H. Lundbeck A/S - Phase I, 2016
H. Lundbeck A/S - Preclinical, 2016
H. Lundbeck A/S - Discovery, 2016
H. Lundbeck A/S - Pipeline by Target, 2016
H. Lundbeck A/S - Pipeline by Route of Administration, 2016
H. Lundbeck A/S - Pipeline by Molecule Type, 2016
H. Lundbeck A/S - Pipeline Products by Mechanism of Action, 2016
H. Lundbeck A/S - Recent Pipeline Updates, 2016
H. Lundbeck A/S - Dormant Developmental Projects,2016
H. Lundbeck A/S - Discontinued Pipeline Products, 2016
H. Lundbeck A/S, Subsidiaries

LIST OF FIGURES

H. Lundbeck A/S - Pipeline by Top 10 Indication, 2016
H. Lundbeck A/S - Pipeline by Stage of Development, 2016
H. Lundbeck A/S - Monotherapy Products in Pipeline, 2016
H. Lundbeck A/S - Partnered Products in Pipeline, 2016
H. Lundbeck A/S - Out-Licensed Products in Pipeline, 2016
H. Lundbeck A/S - Pipeline by Top 10 Target, 2016
H. Lundbeck A/S - Pipeline by Route of Administration, 2016
H. Lundbeck A/S - Pipeline by Molecule Type, 2016
H. Lundbeck A/S - Pipeline Products by Top 10 Mechanism of Action, 2016
Skip to top


P2D Bioscience - Product Pipeline Review - 2015 US$ 1,500.00 Nov, 2015 · 34 pages
PAION AG – Product Pipeline Review – Q1 2011 US$ 500.00 Mar, 2011 · 42 pages

Ask Your Question

H. Lundbeck A/S - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: